

# Index

Note: page numbers in *italics* refer to figures and tables, those in **bold** refer to boxes

- activins, 7
- adenomyosis
  - myometrial cyst, 219
  - ultrasound monitoring for ovulation induction, 218
- adult respiratory distress syndrome (ARDS), 125
- age, chronological and ovarian reserve, 255
- albumin, intravenous
  - OHSS, 123
  - prevention, 117
  - treatment, 122
- polycystic ovarian syndrome, 96
- amenorrhea, hyperprolactinemia, 201–202
- anastrozole, 7, 9
- androgen(s), 7
- androgen priming, poor responders, 83
- anesthesia, OHSS patients, 125–126
- anovulatory patients, 14–22
  - anti-estrogen therapy, 17–18
  - aromatase inhibitors, 20
  - clomiphene citrate, 17–18, 21, 22
  - complications of ovarian stimulation, 21–22
  - diet restriction, 16
  - exercise, 17
  - follicle development, 21–22
  - FSH levels, 15
  - gonadotropin therapy, 18–19
  - hCG, 17, 19
  - hypogonadotropic, 17
  - insulin resistance, 19
  - insulin sensitizers, 19–20
  - interventions, 14–22
  - laparoscopic electrocoagulation of the ovaries, 20
  - lifestyle interventions, 15–17
  - luteal support, 17
  - metformin, 19–20
  - normogonadotropic, 17–20
  - ovarian hyperstimulation syndrome, 21–22
  - overweight/obesity, 15–16
  - pharmacological interventions, 17–20
  - prostaglandin E<sub>2</sub> levels, 15
  - smoking cessation, 16
  - surgical intervention, 20
  - tamoxiphene, 18
  - weight reduction, 15–16, 17
  - WHO criteria, 14
- anterior pituitary
  - Pit-1 gene, 195
  - prolactin secretion, 195
- anti-estrogens
  - anovulatory patients, 17–18
  - intrauterine insemination with mild ovarian hyperstimulation, 29
- anti-Mullerian hormone (AMH)
  - follicular recruitment, 44
  - GnRH agonist use, 44
  - treatment response, 45
- ovarian reserve, 258
- antral follicle count combination, 259
  - polycystic ovarian syndrome, 94
- antibiotics, OHSS, 123
- anticoagulant therapy, OHSS, 122–123
- antidepressants, hyperprolactinemia induction, 199
- antihypertensive agents,
  - hyperprolactinemia induction, 199
- antipsychotic agents,
  - hyperprolactinemia induction, 198, 206
- antithrombin factor II, 9
- antral follicle count (AFC), 182, 188, 224–225
  - age correlation, 255
  - ovarian reserve, 258
  - anti-Mullerian hormone combination, 259
- L-arginine, adjunct in poor responders, 82–83
- aromatase inhibitors, 1, 5–9
  - adverse effects, 7, 9, 20
  - anovulatory patients, 20
  - coagulation disorders, 9
  - early generation, 6
  - problems with, 6
  - endometriosis, 8
- fertility preservation in estrogen-dependent malignancy, 8–9
- GnRH antagonist adjunct in poor responders, 81–82
- injectable gonadotropins
  - concomitant use, 7–8
- intrauterine insemination with mild ovarian hyperstimulation, 28–29
- minimal stimulation protocol, 134
- outcome of treatment, 20
- ovarian stimulation
  - mechanism, 7, 20
  - role, 7–8
- polycystic ovarian syndrome, 8, 91
- pregnancy outcome, 9
- safety, 9, 20
- third generation, 6, 7
  - advantages, 6–7
  - treatment regimen, 20
  - women benefiting, 8–9
- ascites in OHSS, 104, 105, 106, 112
  - management, 124–125
- ascorbic acid, progesterone
  - combination for luteal phase support, 247
- aspirin, progesterone combination for luteal phase support, 248
- assisted reproduction therapy (ART)
  - controlled ovarian stimulation, 151
  - polycystic ovarian syndrome, 92–94
- autoimmune disease, fertility preservation, 190
- bariatric surgery, polycystic ovarian syndrome, 88
- body weight, hCG effects in oocyte maturation, 234–235
- bone morphogenetic protein-15 (BMP-15), OHSS prediction, 110–111
- bromocriptine, 204–205
  - long-acting, 204
- buserelin, OHSS incidence, 94
- cabergoline, 204–205
  - high responders, 147

- OHSS, 116  
 prevention, 119–120  
 cancer survivors, oocyte donation, 189–191  
 cervix, evaluation, 222  
 cetorelix, 50–52  
 natural cycle IVF with GnRH antagonists, 54  
 OHSS prevention, 113–114  
 polycystic ovarian syndrome, 94  
 older patients, 57  
 outcome, 57  
 poor responders, 80  
 structure, 50  
 chest wall injuries, hyperprolactinemia, 201  
 circulatory volume correction, OHSS management, 122  
 clomiphene (clomifene) citrate, 1–5  
 administration regimens, 2–3, 17  
 adverse effects, 1–2, 3–5, 17  
 anovulatory patients, 17–18, 21, 22  
 antiestrogenic effects, 5  
 chemical structure, 2  
 congenital anomalies, 4  
 dosage rate, 2, 89  
 endometrium effects, 5  
 GnRH antagonist  
 adjunct in poor responders, 81–82  
 protocols, 53  
 intrauterine insemination with mild ovarian hyperstimulation, 27–28  
 mechanism of action, 2, 17  
 metformin comparison, 90–91  
 minimal stimulation protocols, 138  
 multi-gestation pregnancy risk, 3, 89–90  
 outcome, 3, 17, 89–90  
 ovarian cancer risk, 3–4  
 ovarian hyperstimulation syndrome, 3  
 ovulation and live birth prediction, 22  
 pharmacokinetics, 2  
 polycystic ovarian syndrome, 89–90  
 pregnancy  
 loss, 4  
 rate, 2–3, 21  
 risk, 1–2  
 resistance, 4–5, 18  
 causes, 5  
 management, 5  
 treatment failure, 4–5, 18  
 causes, 5  
 management, 5  
 clomiphene citrate challenge test (CCCT), 257  
 clomiphene citrate/FSH protocol for mild IVF, 36  
 economics, 38  
 results, 37  
 coagulation disorders, aromatase inhibitors, 9  
 coasting  
 OHSS risk  
 GnRH antagonists, 56  
 polycystic ovarian syndrome, 95  
 reduction, 113, 115  
 protocols for high responders, 136  
 cocaine, hyperprolactinemia induction, 199  
 congenital anomalies  
 clomiphene citrate, 4  
 in vitro maturation, 187  
 controlled ovarian stimulation (COS), 151, 181  
 adjuncts, 82–83  
 assisted reproduction therapy, 151  
 complications, 173  
 cost, 151  
 low-dose hCG, 156–157  
 multi-gestation pregnancy risk, 173  
 natural cycle IVF comparison, 173–174  
 OHSS risk, 173, 181  
 poor responders, 77–84, 175, 176  
 progesterone  
 pathogenesis, 70–73  
 use, 67–74  
 recombinant LH, 155  
 corifollitropin, hypogonadotropic hypogonadism, 168–169  
 Creutzfeldt–Jakob disease, iatrogenic with gonadotropin use, 61  
 cumulus–oocyte complexes (COC), 185, 237–238, 239  
 dehydroepiandrosterone (DHEA), poor responders, 83  
 dermoid cysts, 226–227  
 diuretics, OHSS treatment, 124  
 dopamine  
 OHSS treatment, 124, 125  
 prolactin secretion regulation, 196, 198  
 release, 200  
 synthesis, 200  
 tuberoinfundibular pathway, 196  
 dopamine agonists  
 hyperprolactinemia, 203–205  
 mechanism of action, 204–205  
 OHSS prevention, 118–120  
 serum prolactin concentration effects, 205  
 withdrawal, 205  
 dopamine receptor 2 agonists, 119  
 dydrogesterone, 246  
 ectopic pregnancy, OHSS, 126  
 elective single embryo transfer (eSET), 35–36  
 electrocautery, *see* ovarian cautery  
 electrolyte replacement, OHSS treatment, 122  
 embryo(s)  
 cryopreservation  
 high responders, 136  
 OHSS prevention, 120  
 polycystic ovarian syndrome, 96–97  
 ovarian hyperstimulation, adverse effects, 34–35  
 embryo transfer, in vitro maturation, 185  
 enclomiphene, 2  
 endometrioma, 226  
 endometriosis, aromatase inhibitors, 8  
 endometrium  
 assessment during ovulation  
 induction, 230  
 normal, 221  
 clomiphene citrate effects, 5  
 estrogen exposure, in vitro maturation, 184  
 gene expression disturbances, 34–35  
 polycystic ovarian syndrome, 8  
 polyposis, 223  
 polyps, 220–221  
 feeding vessel, 222  
 sonohysterography, 221, 222  
 progesterone, effects on receptivity, 245  
 receptivity with progesterone use, 69, 70  
 oocyte donors, 69–70  
 oocyte recipients, 70  
 thickness  
 during ovulation induction, 230  
 in vitro maturation, 183–184  
 ultrasound monitoring for ovulation induction, 219–221  
 Erk1 and Erk2, 162, 169  
 estradiol (E<sub>2</sub>)  
 anovulatory patients, 15  
 FSH treatment, 154  
 supplemented with hCG, 156–157  
 hMG treatment, 154  
 luteal phase support with progesterone, 246–247  
 ovarian reserve marker, 256–257  
 protocols for high responders, 135  
 estrogen  
 androgen conversion blocking, 7  
 with clomiphene citrate, 5  
 endometrial exposure in in-vitro maturation, 184  
 hyperprolactinemia treatment, 205–206

## Index

- estrogen (*cont.*)  
 moderation of actions, 1  
 pretreatment in hypogonadotropic hypogonadism, 167–168  
 priming for GnRH antagonist poor responders, 81  
 prolactin secretion regulation, 196–197  
 reduction by aromatase inhibitors, 7  
 estrogen modulators, 1  
 exercise, anovulatory patients, 17  
 exogenous FSH ovarian reserve test (EFORT), 258
- factor V, 9
- fertility preservation  
 autoimmune disease, 190  
 cancer survivors, 189–191  
 in vitro maturation, 189–191
- follicle-stimulating hormone (FSH), 61, 151  
 acidic isoforms, 62–63  
 adverse events, 64  
 age correlation with serum levels, 255  
 anovulatory patient treatment, 15, 18–19  
 dose increase with GnRH antagonists, 53  
 effectiveness, 63–64  
 gonadotropin therapy, 152–155  
 hCG  $\beta$ -subunit of C-terminal peptide attachment, 168–169  
 highly purified, 153  
 hCG supplementation, 156  
 hyperinsulinemia, 19  
 hyperprolactinemia effects, 201  
 hypogonadotropic anovulatory patients, 17  
 isoforms, 62–63  
 IVF, 34–39  
 mild, 35  
 LH pretreatment in hypogonadotropic hypogonadism, 165  
 LH receptor sensitivity of granulosa cells, 71  
 LH surge, 61  
 luteal phase with GnRH agonist, 79  
 minimal stimulation protocol, 133–134  
 molecule, 62  
 ovarian hyperstimulation syndrome, 64  
 ovarian reserve marker, 255–256, 257  
 poor responders, 77  
 premature follicular luteinization, 153  
 preovulatory follicles, 153  
 progesterone levels, 72  
 recombinant, 62, 64, 153  
 $E_2$  levels, 154  
 polycystic ovarian syndrome, 94  
 pregnancy rates, 154  
 prostaglandin levels, 154  
 recombinant LH supplementation, 155–156  
 smoking effects, 16  
 two cell–two gonadotropin hypothesis, 162
- follicle-stimulating hormone (FSH)  
 receptor gene, SNPs, 259
- follicle-stimulating hormone receptors (FSHR)  
 genotype in OHSS prediction, 109–110  
 testosterone augmentation of expression, 7
- follicles  
 development, 233  
 multiple, 42, 44  
 preovulatory with FSH/LH activity, 153
- follicular luteinization, premature, 153
- follicular recruitment  
 anti-Mullerian hormone levels, 44  
 dynamics with GnRH agonists, 44
- follicular rupture, hCG administration timing, 237
- folliculogenesis, FSH supplemented with hCG, 156–157
- follitropin alpha, 62
- follitropin beta, 62
- galactorrhea, hyperprolactinemia, 201–202, 206
- ganirelix, 50, 55  
 OHSS prevention, 113–114  
 polycystic ovarian syndrome, 94  
 structure, 50
- gastrointestinal agents,  
 hyperprolactinemia induction, 199
- glucocorticoids  
 OHSS prevention, 118  
 poor responders, 83
- gonadotropin receptor stimulants, 1
- gonadotropin-releasing hormone (GnRH), 49  
 hyperprolactinemia effects, 201  
 pulsatile therapy in hypogonadotropic hypogonadism, 166–168
- gonadotropin-releasing hormone (GnRH) agonists, 42–47  
 anti-Mullerian hormone levels, 44, 45  
 desensitization regimen, 34–39  
 down-regulation, 43
- dual suppression for high responders, 135–136
- efficacy, 43
- flare effect, 43–44
- flare protocol, 45–46  
 poor responders, 77–78
- follicular recruitment dynamics, 44
- GnRH antagonist comparison, 51–52
- hCG in oocyte maturation, 236–237
- high responders, 137–138
- historical perspectives, 42
- hypogonadotropic anovulatory patients, 17
- intrauterine insemination with mild ovarian hyperstimulation, 28–29
- LH concentration, 46
- LH release, 240
- LH supplementation in poor responders, 78
- LH surge, 47, 93  
 control, 49
- luteal phase FSH in poor responders, 79
- luteal phase recovery, 244
- luteal phase support, 47, 248–249  
 onset, 249  
 oocyte maturation triggering, 241
- microdose flare  
 poor responders, 79–80  
 protocols, 132
- mini-dose luteal phase, 79
- mode of action, 43
- OHSS, 44, 114  
 prediction, 44  
 prevention, 115–116  
 risk, 45
- oocyte maturation induction, 240
- freeze-all strategy combination, 241
- luteal phase support, 241
- oocyte competence effects, 240
- polycystic ovarian syndrome, 94–95  
 triggering of final with GnRH antagonist protocol, 55
- oocyte retrieval, 238
- oral contraceptives before flare protocol, 78
- ovarian cysts, 227
- ovarian reserve, 45
- ovulation triggering in OHSS prevention, 115–116
- poor responders, 132  
 flare protocol, 77–78  
 LH supplementation, 78  
 microdose flare, 79–80  
 mini-dose luteal phase, 79  
 plus luteal phase FSH, 79

## Index

- stop protocols, 78
- progesterone levels, 46, 72
- protocols for ovarian stimulation, 130–131
- recombinant LH, 155
- safety, 44
- stop protocols for poor responders, 78
- treatment, 43–47
- gonadotropin-releasing hormone
  - analog stimulation test (GAST), 257–258
- gonadotropin-releasing hormone (GnRH) antagonists, 49–57
  - adjuncts, 81–82
  - aromatase inhibitors in poor responders, 81–82
  - clomiphene citrate, 53
  - poor responders, 81–82
  - development, 49
  - dose-finding study, 50
  - estrogen priming in poor responders, 81
  - first generation, 49
  - flexible protocol, 53
  - FSH dose increase, 53
- GnRH agonists
  - comparison, 51–52, 133
  - final oocyte maturation triggering, 55
  - flare protocol comparison, 133
  - oocyte maturation induction in polycystic ovarian syndrome, 94–95
- hCG in oocyte maturation, 237
- high responders, 136–137
- human menopausal gonadotropin use, 53
- intrauterine insemination with mild ovarian hyperstimulation, 28–29, 30
- IVF babies, 57
- LH surge, 93
  - control, 49
  - effects, 55
- luteal phase supplementation, 244–245
- meta-analyses, 56
- microdose flare regimen in poor responders, 80–81
- mild IVF, 35
- minimal stimulation, 133–134
  - protocol, 134, 138
- mode of action, 49–50
- natural cycle IVF, 54
- OHSS, 56–57
  - coasting, 56
  - prevention, 113–114, 117
  - prevention in polycystic ovarian syndrome, 94
- older patients, 57
- oral contraceptives before IVF, 53–54
- outcomes, 51–52, 57
- poor responders, 55–56, 80–81
  - adjuncts, 81–82
  - aromatase inhibitors, 81–82
  - clomiphene citrate, 81–82
  - estrogen priming, 81
  - microdose flare regimen, 80–81
- progesterone levels, 72
- protocols for ovarian stimulation, 130–131, 133
- recombinant LH use, 54, 55–56, 155
- single high-dose regimen, 50–52
- structure, 50
- third generation, 49
- gonadotropin therapy, 61–64
  - adverse events, 19, 64
  - anovulatory patients, 18–19
  - conventional regimen, 130
  - effectiveness, 63–64
  - FSH and LH activity, 152–155
  - FSH treatment, 154
  - historical aspects, 61–62
  - hMG treatment, 154
- hypogonadotropic hypogonadism, 163–166
  - complications, 165–166
  - outcome, 165
- iatrogenic CJD, 61
- injectable, 1
- intrauterine insemination with mild ovarian hyperstimulation, 28, 29, 30
- long-term risks, 34
- mechanism of action, 18–19
- multiple pregnancy risk, 19
- OHSS risk, 19, 92, 111–112, 114
- outcome, 19
- physiology of action, 152
- poor responders, 77, 131–132
- treatment regimen, 19
- urinary-derived, 64
- in vitro maturation, 182
- see also* follicle-stimulating hormone (FSH); luteinizing hormone (LH)
- GPR54 gene, 169
- growth hormone (GH)
  - adjunct in poor responders, 82–83, 132, 146
- hMG combination, 167
- IGF-1 combination in
  - hypogonadotropic hypogonadism, 166–167
- hemosiderosis, 168
- human chorionic gonadotropin (hCG)
  - administration routes, 234
- anovulatory patients, 19
  - luteal support in
    - hypogonadotropic patients, 17
- hypogonadotropic hypogonadism, 164
- intrauterine insemination with mild ovarian hyperstimulation, 30
- LH activity, 151–152
- LH surge, 234
- low-dose in controlled ovarian stimulation, 156–157, 158
- luteal phase support, 248
- onset, 249
- luteal support in polycystic ovarian syndrome, 93
- molecule, 63
- OHSS
  - administration delay, 115
  - dosage decrease, 115
  - risk, 240, 248
  - risk in polycystic ovarian syndrome, 95
- oocyte maturation, 233–241
  - administration routes, 234, 235
  - before retrieval, 178–179
  - bodyweight effects, 234–235
  - GnRH agonist long protocol, 236–237
  - GnRH antagonist protocol, 237
  - luteal phase defect, 244
  - minimally effective dose, 235–236
  - outcomes, 238
  - time to follicular rupture, 237
- oocyte retrieval dosage, 239
- perifollicular blood flow, 229–230
- pharmacokinetics, 234, 235
- preparations, 152, 156
- progesterone
  - levels, 67, 73–74
  - for luteal support, 47
  - outcome, 71
- recombinant
  - oocyte maturation, 239–240
  - ovulation induction, 238
  - pharmacokinetics, 238
- reduction in high responders, 136
- serum accumulation from hMG, 71
- thalassemia, 168
- in vitro maturation, 182–183
- human chorionic gonadotropin (hCG)/LH protocol for mild IVF, late follicular phase, 36, 37
- human menopausal gonadotropin (hMG)
  - development, 61–62
  - E<sub>2</sub> levels, 154
  - estrogen pretreatment, 167–168
  - GH adjunct, 167
  - GnRH antagonist protocols, 53
  - highly purified, 62

## Index

- human menopausal gonadotropin (hMG) (*cont.*)  
 gonadotropin dose, 154  
 pregnancy rates, 154  
 hypogonadotropic hypogonadism, 164  
 LH  
 activity, 151  
 content, 64  
 preparations, 152  
 prostaglandin levels, 154  
 serum hCG accumulation, 71  
 thalassemia, 168  
 hydrolaparoscopy, transvaginal, 211  
 hydrosalpinges, 227–228  
 hydroxyethyl starch solution (HES), OHSS, 117–118, 122, 123  
 hyperinsulinemia, FSH levels, 19  
 hyperprolactinemia, 195–207  
 anovulatory patients, 14  
 causes, 197–201  
 physiologic, 197–198  
 clinical manifestations, 201–202  
 diagnosis, 201–202  
 dopamine agonists, 203–205  
 estrogen therapy, 205–206  
 evaluation, 202–203  
 galactorrhea, 201–202, 206  
 hypogonadism, 201  
 hypothyroidism, 198, 206  
 idiopathic, 200, 203  
 imaging, 202–203  
 infertility, 201  
 laboratory tests, 202–203  
 macroprolactinemia, 200  
 management, 203–206  
 osteopenia/osteoporosis, 201  
 pathologic causes, 198–201  
 pharmacologic agents, 198–200, 206  
 with pituitary lesions, 203–204  
 prolactinoma, 198  
 radiation therapy, 206  
 surgical treatment, 206  
 withdrawal of therapy, 205  
 without pituitary lesions, 203  
 hypogonadism, hyperprolactinemia, 201  
 hypogonadotropic hypogonadism, 162–169  
 classification, 163  
 clinical features, 162  
 corifollitropin therapy, 168–169  
 Erk1 and Erk2, 162, 169  
 estrogen pre-treatment, 167–168  
 FSH treatment with LH pretreatment, 165  
 GH/IGF-1 administration, 166–167  
 GnRH treatment, 166–168  
 gonadotropin therapy, 163–166  
 complications, 165–166  
 outcome, 165  
 hCG treatment, 164  
 hMG treatment, 164  
 kisspeptin, 162  
 kisspeptin-GPR54 complex, 169  
 LH treatment, 164–165  
 luteal support, 164, 168  
 OHSS with gonadotropin therapy, 165–166  
 ovulation induction, 151  
 protocols, 163–169  
 hypothalamus disease, 198  
 hypothyroidism  
 hyperprolactinemia, 198, 206  
 prolactin secretion, 199  
 implantation window, in vitro maturation, 183–184  
 in vitro fertilization (IVF), 181  
 babies in GnRH antagonist cycles, 57  
 clomiphene citrate/FSH protocol, 36  
 economics, 38  
 results, 37  
 conventional ovarian stimulation, 34–35  
 intrauterine insemination with mild ovarian hyperstimulation comparison, 31  
 late follicular phase hCG/LH protocol, 36  
 results, 37  
 luteal phase  
 abnormality, 244–245  
 support, 244–250  
 mild, 34–39  
 definition, 35  
 embryo quality, 37–38  
 health economics, 38  
 patient groups, 38–39  
 pregnancy rate, 38  
 psychological burden, 38–39  
 rationale, 35  
 regimens, 36  
 results, 36–38  
 success rates, 36–37  
 modified cycle, 36  
 natural cycle, 173–179  
 oral contraceptives before in GnRH antagonist cycles, 53–54  
 polycystic ovarian syndrome, 93–94  
 poor responders, 173–174  
 protocol selection for ovarian stimulation, 130–138  
 short antagonist protocol with low dose FSH, 36, 37  
*see also* controlled ovarian stimulation (COS); natural cycle IVF  
 in vitro maturation (IVM) of oocytes, 181–191  
 antral follicle count, 182, 188  
 assisted hatching, 185  
 blastocyst transfer, 185  
 congenital abnormalities, 187  
 cumulus–oocyte complexes, 185  
 embryo implantation rate, 186  
 embryo transfer, 185  
 embryology laboratory procedures, 185  
 endometrium  
 estrogen exposure, 184  
 thickness, 183–184  
 fertility preservation, 189–191  
 gonadotropin therapy, 182  
 hCG administration, 182–183  
 high responders, 138  
 ICSI, 185  
 immature oocyte use, 181–182  
 implantation window, 183–184  
 indications, 188–191  
 karyotype, 187  
 luteal support, 185–186  
 multi-gestation pregnancy, 186, 187  
 neuromotor development, 187  
 obstetric outcome, 187  
 OHSS prevention, 120  
 oocytes  
 collection, 184–185  
 cryopreservation, 189–190  
 donation, 188–189, 190  
 outcome, 186–187  
 physical development, 187  
 polycystic ovarian syndrome, 96–97, 186–187  
 poor responders to gonadotropin stimulation, 188  
 pregnancy  
 loss, 186–187  
 rate, 186  
 treatment cycle, 182–185  
 monitoring/management, 182–184  
 indomethacin, OHSS treatment, 124  
 infertility, hyperprolactinemia, 201  
 inhibin B, ovarian reserve marker, 257  
 insulin-like growth factor 1 (IGF-1)  
 androgen stimulation, 7  
 GH combination in hypogonadotropic hypogonadism, 166–167  
 insulin resistance  
 anovulatory patients, 19  
 polycystic ovarian syndrome, 16, 19  
 insulin sensitizers, 1  
 adverse effects, 20  
 anovulatory patients, 19–20  
 mechanism of action, 19  
 outcome of treatment, 19  
 treatment regimen, 19



## Index

- International Society for Mild Approaches in Assisted Reproduction (ISMAAR), 35
- intracytoplasmic sperm injection (ICSI), 173
- in vitro maturation, 185
- intrauterine insemination, polycystic ovarian syndrome, 92–93
- intrauterine insemination with mild ovarian hyperstimulation, 27–31
- anti-estrogens, 29
- drug choice, 27–29
- GnRH agonists, 28–29
- GnRH antagonists, 28–29, 30
- gonadotropins, 29, 30
- hCG treatment, 30
- indications, 27
- IVF comparison, 31
- LH surges, 28–29, 30
- luteal support, 29
- multi-gestation pregnancy avoidance, 30–31
- optimal timing, 29–30
- outcome, 28, 29
- ovarian hyperstimulation syndrome avoidance, 30–31
- progesterone use, 29
- risks, 30–31
- semen preparation, 31
- treatment cycles, 30
- intrauterine synechiae, 221, 223
- karyotype, in vitro maturation, 187
- Kiss-1 gene, 162
- kisspeptin, 162, 165
- kisspeptin-GPR54 complex, 169
- lactogenic hormone/lactotropin, *see* prolactin
- lactotroph(s)
- hyperplasia, 197–198
- prolactin secretion, 195, 196
- lactotroph adenomas, 198, 201–202
- estrogen therapy, 205–206
- surgical interventions, 206
- laparoscopic electrocoagulation of the ovaries (LEO), 20
- laparoscopic ovarian diathermy
- consensus statements, 214
- OHSS prevention, 118
- polycystic ovarian syndrome, 91–92
- premature ovarian failure, 212–213
- see also* ovarian cautery
- laparoscopic ovarian multi-needle intervention (LOMNI), 212
- laser ovarian cautery, 209–210
- complications, 213
- letrozole, 1, 7
- adverse effects, 9, 20
- endometrium effects, 8
- estrogen level lowering, 7
- GnRH antagonists in poor responders, 82
- minimal stimulation protocol, 134
- outcome of treatment, 20
- polycystic ovarian syndrome, 8, 91
- pregnancy outcome, 9
- rosiglitazone combination, 8
- safety, 9, 20
- treatment regimen, 20
- leuprolide, microdose flare with GnRH agonist, 79
- lifestyle change, polycystic ovarian syndrome, 88
- luteal phase, 244
- hCG-induced defect, 244
- insufficiency, 244–245
- late and stimulation starting, 132
- progesterone role, 245
- luteal phase support, 245–249
- duration, 249–250
- GnRH agonists, 47, 248–249
- onset, 249
- oocyte maturation triggering, 241
- hCG, 248
- onset, 249
- hypogonadotropic hypogonadism, 164, 168
- in vitro maturation, 185–186
- IVF, 244–250
- onset, 249
- polycystic ovarian syndrome, 93
- progesterone, 245
- ascorbic acid combination, 247
- aspirin combination, 248
- co-treatments, 247–248
- estradiol combination, 246–247
- intramuscular, 246
- oral, 245–246
- prednisolone, 247
- vaginal, 246
- luteal suppression, protocols for ovarian stimulation, 130–131
- luteinization, premature, 67
- luteinizing hormone (LH)
- activity components, 151–152
- anovulatory patient treatment, 18–19
- follicular level elevation with progesterone, 70–71
- GnRH agonist use, 46
- gonadotropin therapy, 152–155
- human menopausal gonadotropin, 64
- hyperprolactinemia effects, 201
- hypogonadotropic anovulatory patients, 17
- hypogonadotropic hypogonadism, 164–165
- meiosis resumption stimulation, 233
- molecule, 63
- preovulatory follicles, 153
- recombinant, 62, 151–152, 155–156
- FSH supplementation, 155–156
- with GnRH antagonist cycles, 54, 55–56
- hypogonadotropic hypogonadism, 165
- OHSS prevention, 116–117
- oocyte maturation, 240
- sensitivity and ovarian response, 71
- surges in intrauterine insemination with mild ovarian hyperstimulation, 28–29, 30
- two cell–two gonadotropin hypothesis, 162
- luteinizing hormone/chorionic gonadotropin (LH/CG)
- receptor, 152, 156
- luteinizing hormone (LH) receptor, sensitivity of granulosa cells to FSH, 71
- luteinizing hormone (LH) surge, 42
- FSH use, 61
- GnRH agonists, 47, 93
- GnRH antagonists, 49, 55, 93
- GnRH control, 49
- hCG use, 234
- premature, 49, 67
- luteoplacental shift, 244
- luteotropic hormone/luteotropin, *see* prolactin
- macroprolactinemia, 200
- malignancies, estrogen-dependent and fertility preservation, 8–9
- menotropins, *see* human menopausal gonadotropin (hMG)
- metformin
- adverse effects, 20
- anovulatory patients, 19–20
- clomiphene citrate comparison, 90–91
- OHSS prevention, 118
- outcome of treatment, 19, 90–91
- polycystic ovarian syndrome, 90–91
- co-administration with gonadotropin stimulation, 95–96
- treatment regimen, 19
- miscarriage
- rate with polycystic ovarian syndrome, 186–187
- risk
- clomiphene citrate, 4
- in vitro maturation, 186–187
- Müllerian anomalies, ultrasound monitoring for ovulation induction, 219

## Index

- multi-gestation pregnancy
  - avoidance in intrauterine insemination with mild ovarian hyperstimulation, 30–31
- clomiphene citrate, 3
- controlled ovarian stimulation, 173
- gonadotropin therapy in
  - hypogonadotropic hypogonadism, 165
- risk with gonadotropin therapy, 19
- in vitro maturation, 186, 187
- myometrial cyst, 219
- natural cycle IVF, 36, 173–179
  - cost, 178
  - efficacy, 178
  - with GnRH antagonists, 54
  - modified, 178
  - oocyte retrieval, 174, 178
    - failure, 179
  - outcome, 176–178
  - poor responders, 173–178
    - age of women, 177
    - cycles, 177
  - pregnancy rate, 176–178
  - protocol, 178
- necklace sign, OHSS prediction, 112–113
- neuromotor development, in vitro maturation, 187
- obesity
  - anovulatory patients, 15–16
  - hCG effects in oocyte maturation, 234–235
  - laparoscopic ovarian diathermy resistance, 92
  - polycystic ovarian syndrome, 87–88
- oocyte(s)
  - cryopreservation, 189–190
  - immature, 181–182
  - meiosis, 182
  - metaphase II stage, 181, 185
  - quality and progesterone administration, 69, 70
    - oocyte donors, 69–70
    - oocyte recipients, 70
- oocyte donation, 69–70
  - in vitro maturation, 188–189, 190
- oocyte maturation, 233
  - GnRH agonists in polycystic ovarian syndrome, 94–95
  - with hCG, 178–179
  - regulation, 233
- oocyte maturation, triggering of final, 233–241
  - GnRH, 240
  - GnRH agonists, 55
    - freeze-all strategy combination, 241
  - hCG, 233–241
    - administration routes, 234, 235
    - bodyweight effects, 234–235
    - GnRH agonist long protocol, 236–237
    - GnRH antagonist protocol, 237
    - minimally effective dose, 235–236
    - optimal time to oocyte retrieval, 237–240
    - outcomes, 238
    - recombinant, 239–240
    - time to follicular rupture, 237
  - recombinant LH, 240
- oocyte retrieval
  - GnRH agonists, 238
  - hCG administration
    - dosage, 239
    - optimum time, 237–240
  - in vitro maturation, 184–185
  - natural cycle IVF, 174, 178
    - failure, 179
- opiates, hyperprolactinemia induction, 199
- oral agents, 1–9
- oral contraceptives
  - before IVF
    - GnRH agonist cycles, 78
    - GnRH antagonist cycles, 53–54
  - dual suppression for high responders, 135–136
- osteopenia/osteoporosis, hyperprolactinemia, 201
- ovarian adhesions, 212
- ovarian cancer, clomiphene citrate, 3–4
- ovarian cautery
  - bilateral, 210–211
  - blood supply impairment, 213
  - consensus statements, 214
  - costs, 213
  - drilling
    - complications, 212–213
    - methods, 209–211
    - outcomes, 210
  - efficacy, 214
  - evidence-based meta-analyses, 214
  - expert opinion, 214
  - laparoscopic ovarian diathermy
    - consensus statements, 214
    - OHSS prevention, 118
  - polycystic ovarian syndrome, 91–92
  - premature ovarian failure, 212–213
- laparoscopic ovarian multi-needle intervention, 212
- laser
  - complications, 213
  - methods, 209–210
- mechanism of action, 213–214
- ovarian adhesion risk, 212
- pelvic adhesion risk, 212
- polycystic ovarian syndrome, 209–214
  - premature ovarian failure, 212–213
- transvaginal hydrolaparoscopy, 211
- ultrasound-guided transvaginal ovarian needle drilling, 211–212
- unilateral, 210–211
- unipolar, 209
- ovarian cysts
  - dermoid, 226–227
  - functional, 227
  - hemorrhagic, 227
  - para-ovarian, 227
  - ruptured, 125
- ovarian failure, premature, 212–213
- ovarian hyperstimulation, mild
  - efficacy, 178
  - intrauterine insemination, 27–31
  - normal responders, 173, 178
  - pregnancy rate, 178
- ovarian hyperstimulation syndrome (OHSS), 103–126
  - abdominal paracentesis, 98, 124
  - adult respiratory distress syndrome, 125
  - anesthesia, 125–126
  - anovulatory patients, 21–22
  - antibiotic treatment, 123
  - anticoagulant therapy, 122
    - duration, 123
    - prophylactic, 122–123
  - ascites, 104, 105, 106, 112
    - management, 124–125
  - aspiration procedures, 124–125
  - autotransfusion of ascitic fluid, 125
  - avoidance in intrauterine insemination with mild ovarian hyperstimulation, 30–31
  - biochemical monitoring, 122
  - BMP-15, 110–111
  - cabergoline in prevention, 116, 119–120
  - circulatory volume correction, 122
  - classifications, 97, 103–106, 107, 108
  - clinical features, 103
  - clinical monitoring, 122
  - clomiphene citrate, 3
  - coasting, 113, 115
    - GnRH antagonists, 56
    - polycystic ovarian syndrome, 95
  - controlled ovarian stimulation, 151, 173, 181
  - cycle cancellation, 96, 115
  - cystic ovaries, 103
  - diuretics, 124
  - dopamine agonists, 118–120
  - dopamine treatment, 124, 125
  - early-onset, 57

## Index

- ectopic pregnancy, 126  
 electrolyte replacement, 122  
 embryo cryopreservation, 120  
 follicular monitoring by ultrasound, 112–113  
 FSH receptor genotype, 109–110  
 FSH use, 64  
 glucocorticoids, 118  
 GnRH agonists, 44, 114, 116  
   hCG substitution, 137–138  
   ovulation triggering, 115–116  
   prediction, 44  
   risk, 45  
 GnRH antagonists, 56–57  
   coasting, 56  
   prevention, 113–114, 117  
 gonadotropin therapy, 114  
   hypogonadotropic hypogonadism, 165–166  
   risk, 19, 92, 111–112  
 hCG  
   dosage decrease, 115  
   risk, 240, 248  
 hydroxyethyl starch solution, 117–118, 122, 123  
 in vitro maturation, 120  
 incidence, 103  
 indomethacin, 124  
 inpatient care, 98  
 intravenous albumin, 117, 122, 123  
 IVF, 34  
 laparoscopic ovarian diathermy, 118  
 metformin, 118  
 mild, 104–105  
 moderate, 104–105  
   outpatient management, 120  
 outpatient management, 97–98, 120–121  
 ovarian torsion management, 125–126  
 pathophysiology, 106–107, 109  
 pericardiocentesis, 125  
 pleural effusion, 107  
 pleurocentesis, 125  
 polycystic ovarian syndrome, 92, 113  
   prevention, 94–95  
   risk, 94–97  
 polycystic ovaries, 111, 112–113  
 prediction, 107–111, 112–113  
 pregnancy termination, 126  
 prevention, 113–120  
   primary, 115  
   secondary, 115  
 pulmonary complications, 125  
 quinagolide in prevention, 120  
 ruptured cyst management, 125  
 secondary prevention, 241  
 severe, 105–106  
   in-hospital management, 121  
   outpatient management, 121  
   prediction, 109  
   thromboembolism risk, 122  
 transvaginal ultrasound-guided aspiration, 124  
 treatment, 120–126  
   medical, 122–124  
   surgical, 125–126  
 treatment, factors influencing, 111–112  
 twin pregnancy, 112  
 tyrosine hydroxylase, 119  
 VEGF expression, 116–117, 118–119  
 VEGF receptors, 110  
 venous thrombosis risk, 122  
 ovarian reserve, 255–259  
   anti-Müllerian hormone levels, 258  
   antral follicle count, 258  
   chronological age, 255  
   estradiol levels, 256–257  
   FSH levels, 255–256, 257  
   FSH receptor gene SNPs, 259  
   GnRH agonists, 45  
   inhibin B levels, 257  
   markers, 255–259  
     combination, 259  
     dynamic, 257–258  
   ovarian stimulation guide, 259  
   ovarian volume, 257  
   screening, 255  
   tests, 256  
 ovarian response, pregnancy rate, 69  
 ovarian torsion, OHSS, 125–126  
 ovarian volume  
   age correlation, 255  
   assessment, 223–224  
   OHSS prediction, 113  
   ovarian reserve marker, 257  
 ovaries  
   abnormalities, 225–228  
   assessment, 222–228  
     failure to visualize, 230  
     normal, 223–225  
   cystic, 103  
   kissing, 226  
   laparoscopic surgery, 209  
   polycystic, 225  
     OHSS, 111, 112–113  
     site, 222–223  
     wedge resection, 209, 213  
 overweight  
   anovulatory patients, 15–16  
   see also obesity  
 ovulation induction, 151  
   hypogonadotropic hypogonadism, 162–169  
   protocols, 163–169  
   pretreatment evaluation, 217  
   thalassemia, 168  
   US monitoring, 217–230  
 paracentesis, abdominal in OHSS, 98, 124  
 pelvic adhesions, 212  
 endometrioma, 226  
 pergolide, 204  
 pericardiocentesis, OHSS, 125  
 perifollicular blood flow, 229–230  
 peritoneal/pseudoperitoneal cysts, 228, 229  
 physical development, in vitro  
   maturation, 187  
 pioglitazone, 19  
 Pit-1 gene, 195  
 pituitary adenoma, 203–204  
   dopamine agonist treatment, 205  
   macroadenoma, 202, 204  
   surgical interventions, 206  
   recurrence, 205  
   side effects, 205  
   surgical interventions, 206  
 pituitary gland, disease, 198  
 pleural effusion, OHSS, 107  
 pleurocentesis, OHSS, 125  
 polycystic ovarian syndrome (PCOS), 87–98  
   anovulatory patients, 14  
   anti-Müllerian hormone, 94  
   aromatase inhibitor use, 8, 91  
   assisted conception, 92–94  
   clinical features, 87  
   clomiphene citrate, 89–90  
   coasting, 95  
   criteria, 14, 87  
   cycle cancellation, 96  
   definition, 14, 87  
   diet restriction, 16  
   embryo cryopreservation, 96–97  
   endometrium, 8  
   hCG dose, 95  
   in vitro fertilization, 93–94  
   in vitro maturation, 96–97, 186–187  
   insulin resistance, 16, 19  
   insulin sensitizers, 1  
   intrauterine insemination, 92–93  
   intravenous albumin, 96  
   laparoscopic ovarian diathermy, 91–92  
   letrozole, 91  
   luteal support, 93  
   metformin, 90–91  
   co-administration with  
     gonadotropin stimulation, 95–96  
   miscarriage rate, 186–187  
   obesity, 87–88  
   OHSS, 113  
   prediction of severe, 109  
   prevention, 94  
   risk, 92, 94–97  
   ovarian cauterization, 209–214



## Index

- polycystic ovarian syndrome (PCOS) (*cont.*)  
   patient characteristics, 15  
   pharmacological ovulation induction, 89–91  
   power Doppler, 225  
   recombinant FSH, 94  
   sex hormone-binding globulin, 19  
   vascular endothelial growth factor, 95, 96  
   weight loss, 88  
 polycystic ovaries, 225  
   OHSS, 111  
   prediction, 112–113  
 poor responders to ovarian stimulation, 77–84  
   adjuncts to controlled ovarian stimulation, 82–83  
   androgen priming, 83  
   controlled ovarian stimulation, 175, 176  
   dehydroepiandrosterone, 83  
   FSH dose, 77  
   glucocorticoids, 83  
   GnRH agonists  
     flare protocol, 77–78  
     LH supplementation, 78  
     microdose flare, 79–80  
     mini-dose luteal phase, 79  
     plus luteal phase FSH, 79  
     stop protocols, 78  
   GnRH antagonists, 80–81  
     adjuncts, 81–82  
     estrogen priming, 81  
     microdose flare regimen, 80–81  
   gonadotropin therapy, 77  
   growth hormone adjunct, 82–83  
   in vitro maturation, 188  
   investigated protocols, 78  
   natural cycle IVF, 173–178  
     age of women, 177  
     cycles, 177  
   prednisolone, progesterone combination for luteal phase support, 247  
 pregnancy  
   ectopic, 126  
   prolactin levels, 197  
   *see also* multi-gestation pregnancy  
 pregnancy loss  
   clomiphene citrate, 4  
   in vitro maturation, 186–187  
 polycystic ovarian syndrome, 186–187  
 pregnancy termination, OHSS, 126  
 premature follicular luteinization, 153  
 progesterone  
   controlled ovarian stimulation, 67–74  
   pathogenesis, 70–73  
   endometrial receptivity, 69, 70, 245  
     oocyte donors, 69–70  
     oocyte recipients, 70  
   follicular LH level elevation, 70–71  
   follicular phase secretion, 153  
   FSH administration, 72  
   GnRH agonist use, 46, 72  
   GnRH antagonist use, 72  
   hCG administration, 67, 73–74  
     outcome, 71  
   intrauterine insemination with mild ovarian hyperstimulation, 29  
   LH receptor sensitivity of granulosa cells, 71  
   LH sensitivity and ovarian response, 71  
   luteal phase role, 245  
   luteal phase support, 245  
     ascorbic acid combination, 247  
     aspirin combination, 248  
     co-treatments, 247–248  
     estradiol combination, 246–247  
     hCG induction of ovulation and luteinization, 47  
     hypogonadotropic anovulatory patients, 17  
     intramuscular, 246  
     oral, 245–246  
     prednisolone, 247  
     vaginal, 246  
   multivariant approach, 71–73  
   oocyte quality, 69, 70  
     oocyte donors, 69–70  
     oocyte recipients, 70  
   ovarian response, 73  
   pregnancy rate, 67–69, 73  
   premature luteinization, 67  
   serum accumulation of hCG from hMG, 71  
   thalassemia, 168  
   uterine-relaxing properties, 245  
 prolactin, 195–197  
   angiogenic effects, 196  
   anovulatory patients, 14  
   anti-angiogenic effects, 196  
   functions, 195–196  
   hypothyroidism effects, 199  
   measurement of levels, 202  
   pregnancy levels, 197  
   secretion, 195, 196  
     pulsatile, 197  
     regulation, 196–197  
     stimuli, 197–198  
   structure, 195  
   *see also* hyperprolactinemia  
   prolactin inhibitory factor (PIF), *see* dopamine  
   prolactin-releasing factors (PRF), 196  
   prolactin-releasing peptide 31, 197  
   prolactinoma, 198  
   protease inhibitors, hyperprolactinemia induction, 199  
   protocols for ovarian stimulation, 130–138  
     coasting, 136  
     conventional regimen, 130–131  
     dual suppression with oral contraceptives and GnRH agonists, 135–136  
     embryo cryopreservation, 136  
     GnRH agonists, 130–131, 132  
     hCG substitution, 137–138  
     micro-dose flare protocols, 132  
     GnRH antagonists, 130–131, 133, 136–137  
     growth hormone adjuvant treatment, 132, 146  
     hCG reduction, 136  
     high responders, 131, 134  
     long, 130–131  
     minimal stimulation, 133–134, 138  
     natural cycle, 134  
     normal responders, 131  
     poor responders, 131–134  
       natural cycle, 134  
     regimen development, 130  
     short, 130–131  
   quinagolide (quinoglide), 204–205  
     OHSS prevention, 120  
   radiation therapy, hyperprolactinemia, 206  
   renal failure, hyperprolactinemia, 201  
   rosiglitazone, 19  
     letrozole combination, 8  
   Rotterdam consensus, polycystic ovarian syndrome, 14, 87  
   selective estrogen receptor modulators (SERMs), 1  
   semen preparation, intrauterine insemination with mild ovarian hyperstimulation, 31  
   sex hormone-binding globulin (SHBG), 19  
   single embryo transfer, 35–36  
   single nucleotide polymorphisms (SNPs), FSH receptor gene, 259  
   smoking  
     cessation for anovulatory patients, 16  
     FSH levels, 16  
   sonohysterography, 218, 221–222  
   Stein–Lewenthal syndrome, *see* polycystic ovarian syndrome (PCOS)  
   stress, IVF-related, 34  
   surgical interventions

anovulatory patients, 20	cervix evaluation, 222	uterus
hyperprolactinemia, 206	endometrium, 219–221	anomalies, 219
laparoscopic, 209	assessment during ovulation	arcuate, 219, 220
OHSS, 125–126	induction, 230	assessment, 217–218
	normal, 221	bicornuate, 219, 220
tamoxifen (tamoxiphene)	polyposis, 223	fibroids, 217–218
anovulatory patients, 18	polyps, 220–221, 222	ovulation induction pretreatment
with clomiphene citrate, 5	hydrosalpinges, 227–228	evaluation, 217
thalassemia, ovulation induction, 168	methods, 228–230	progesterone effects, 245
thromboembolism, OHSS	Müllerian anomalies, 219	septate, 219
complication, 122	ovary assessment, 222–228,	sonohysterography, 218, 221–222
thrombophilia gene mutations, 9	230	subseptate, 219
thyrotropin-releasing hormone (TRH),	pelvic peritoneum/tubes assessment,	unicornuate, 219, 220
198	217	
transvaginal hydrolaparoscopy, 211	perifollicular blood flow, 229–230	vascular endothelial growth factor
transvaginal ultrasound-guided	peritoneal/pseudoperitoneal cysts,	(VEGF)
aspiration, 124	228, 229	expression in OHSS, 116–117,
tuberoinfundibular dopamine pathway,	problems encountered, 230	118–119
196	sonohysterography, 221–222	polycystic ovarian syndrome, 95, 96
two cell–two gonadotropin hypothesis,	three-dimensional technique, 224,	vascular endothelial growth factor
162	229	receptors (VEGFR), OHSS,
tyrosine hydroxylase, 119	timing, 229	110
	transvaginal 2-dimensional, 228–229	venous thrombosis, OHSS
ultrasound-guided transvaginal	uterine fibroids, 218	complication, 122
ovarian needle drilling	uterocervical angle, 223	
(UTND), 211–212	VOCAL technique, 224, 229	World Health Organization
ultrasound monitoring for ovulation	<i>see also</i> ovarian cysts; ovaries,	(WHO), anovulatory patient
induction, 217–230	assessment; uterus	classification, 14
adenomyosis, 218, 219	urofollitropin, 62	
antral follicle count (AFC), 224–225	uterocervical angle, 223	zuclophene, 2